Aug 17, 2023 / 02:30PM GMT
Swayampakula Ramakanth - H.C. Wainwright & Co., LLC, LLC - Analyst
Greetings and thanks for joining us to have a conversation with Julie Eastland, CEO; and Luke Walker, CMO of Harpoon Therapeutics. Harpoon is developing next-generation tumor activated T cell engagers and has developed three different platforms: TriTAC, ProTriTAC, and TriTAC-XR. The company also has three drugs in clinical development and several preclinical molecules. To discuss the company's development strategy in '23 and beyond, I welcome Julie and Luke to this fireside chat.
Good morning, Julie and Luke. Thank you for joining us and really appreciate you accepting our invitation and to talk to our audience this morning.
Julie Eastland - Harpoon Therapeutics, Inc. - President and CEO
Thank you, RK. Actually, thanks for having us. We appreciate it.
Questions and Answers:
Swayampakula Ramakanth - H.C. Wainwright & Co., LLC, LLC - AnalystSo just to get started, Julie, for people who are new to Harpoon, could you please give us